Mutations
TREM2
Search Results
TREM2 (68)
Mutation | Pathogenicity | DNA Change | Expected RNA | Protein Consequence | Coding/Non-Coding | Genomic Region | Neuropathology | Biological Effect | Primary Papers |
---|---|---|---|---|---|---|---|---|
rs9357347 |
AD : Possible Risk Modifier | Substitution | Non-Coding | Intergenic - TREM locus | Unknown. |
Predicted to influence transcription factor binding; 6 percent increase in expression of TREM2 and TREML1 in temporal cortex. |
Carrasquillo et al., 2017 | |
c.-5030G>C (rs7759295) |
AD : Unclear Pathogenicity | Substitution | Non-Coding | Upstream | This variant was associated with a higher burden of neurofibrillary tangles in subjects from three prospective cohort studies, but not with amyloid plaques, amyloid angiopathy, Lewy body pathology, terminally activated microglia, or cerebral infarcts. |
Unknown. |
Replogle et al., 2015 | |
c.-2986T>C (rs7748777) |
AD : Possible Risk Modifier | Substitution | Non-Coding | Upstream | Unknown. |
Unknown. |
Wang et al., 2015 | |
E14Ter |
NHD : Pathogenic | Substitution | Substitution | Nonsense | Coding | Exon 1 | Unknown. |
Premature truncation codon; no transcripts detected. |
Paloneva et al., 2003 |
c.40+3 delAGG |
FTD : Pathogenic | Deletion | Splicing Alteration | | Non-Coding | Intron 1 | Unknown; MRI showed brain atrophy, including thinning of the corpus callosum. |
Reduction in the level of TREM2 transcripts. |
Chouery et al., 2008 |
S16F |
AD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown. |
Unknown. |
Sirkis et al., 2016 |
G17E |
AD : Unclear Pathogenicity, FTD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown. |
Predicted benign by Polyphen-2, tolerated by SIFT, neutral by SNPs&Go. |
Cuyvers et al., 2014 |
V27M |
AD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown. |
Normal protein maturation in HEK293 cells. |
Sirkis et al., 2016 |
A28V |
AD : Benign, FTD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown. |
Normal protein maturation and increased cell-surface expression in HEK293 cells. |
Sims et al., 2017 |
S31F |
AD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown. |
Normal protein maturation, decreased total and cell-surface expression in HEK293 cells. |
Sirkis et al., 2016 |
Q33Ter |
NHD : Pathogenic, FTD : Pathogenic, AD : Possible Risk Modifier | Substitution | Substitution | Nonsense | Coding | Exon 2 | Unknown for homozygous carriers; MRI showed cerebral atrophy. Heterozygous AD patient showed typical AD pathology. |
Loss of TREM2 expression. |
Soragna et al., 2003; Guerreiro et al., 2013 |
Y38C |
FTD : Pathogenic | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown; MRI shows cortical atrophy and white matter abnormalities. |
Alters post-translational processing of TREM2, ligand binding, and TREM2-mediated phagocytosis. |
Guerreiro et al., 2013 |
D39G |
AD : Unclear Pathogenicity, FTD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown. |
Predicted to be benign by Polyphen-2, tolerated by SIFT, and neutral by SNPs&Go. |
Cuyvers et al., 2014 |
D39E |
AD : Benign, FTD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 2 | Not applicable. |
Predicted to be possibly damaging by Polyphen-2, but to be tolerated by SIFT and neutral by SNPs&Go. |
Sims et al., 2017 |
H43Y |
AD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown. |
Predicted benign by PolyPhen2. |
Pottier et al., 2013 |
W44Ter |
NHD : Pathogenic | Substitution | Substitution | Nonsense | Coding | Exon 2 | Brain atrophy reported. |
Predicted to result in truncated protein lacking transmembrane and cytoplasmic domains. |
Paloneva et al., 2002 |
G45E |
AD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown. |
Unknown. |
Jonsson et al., 2013 |
R47C |
AD : Unclear Pathogenicity, FTD : Pathogenic | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown, but MRI showed symmetric frontal and temporal lobe atrophy in homozygous carrier. |
Normal protein maturation, decreased total and cell-surface expression in HEK293 cells. |
Sirkis et al., 2016; Ng et al., 2018 |
R47H |
AD : Risk Modifier, FTD : Possible Risk Modifier, PD : Possible Risk Modifier, ALS : Possible Risk Modifier | Substitution | Substitution | Missense | Coding | Exon 2 | AD patients heterozygous for the R47H variant: generally typical AD pathology, but subtle differences compared to non-carriers, including decreased microglial coverage of amyloid plaques and accumulation of phagosomes in microglia. |
Decreased ligand binding to TREM2 and impaired TREM2-mediated activation. |
Guerreiro et al., 2013; Jonsson et al., 2013 |
W50C |
NHD : Pathogenic | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown; imaging showed brain atrophy, diffuse white-matter hyperintensities, thinning of the corpus callosum, and basal ganglia calcification. |
Unknown; predicted to be harmful in silico by Polyphen-2 and SIFT. |
Dardiotis et al., 2017 |
R52C |
FTD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 2 | MRI showed diffuse brain atrophy and ventricular enlargement. |
Unknown. |
Soares et al., 2020 |
R52H |
AD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown. |
Lower cell-surface expression than wild-type TREM2 when co-expressed with its adaptor protein DAP12 in a reporter cell line, but activation by phospholipids similar in cells expressing R52H and wild-type TREM2. |
Jin et al., 2014 |
G58A |
AD : Unclear Pathogenicity, FTD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown. |
Predicted by Polyphen2 to be probably damaging, by SIFT to be tolerated, and by SNPs&Go to be neutral. |
Cuyvers et al., 2014 |
R62C |
AD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown. |
Lower cell-surface expression than wild-type TREM2 when co-expressed with its adaptor protein DAP12 in a reporter cell line; activation by lipid ligands reduced in cells expressing R62C compared with cells expressing wild-type TREM2. |
Pottier et al., 2013; Song et al., 2017 |
R62H |
AD : Risk Modifier | Substitution | Substitution | Missense | Coding | Exon 2 | AD patients heterozygous for the R62H variant: decreased microglial coverage of amyloid plaques and increased accumulation of phagosomes in microglia, compared to non-carriers. |
Decreased ligand binding to TREM2 and impaired TREM2-mediated activation. |
Jin et al., 2014; Sims et al., 2017 |
T66M |
FTD : Pathogenic | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown; MRI showed frontal lobe atrophy, ventricular enlargement, and white-matter abnormalities in one homozygous carrier, and frontal and parietal lobe atrophy in two other homozygous carriers. |
Greatly decreased cell-surface expression and shedding of sTREM2, reduced ligand binding, and impaired phagocytosis. |
Guerreiro et al., 2013 |
N68K |
AD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown. |
Predicted benign by PolyPhen2; apparently normal protein folding. |
Guerreiro et al., 2013 |
L72V |
AD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown. |
Predicted by SIFT to be tolerated but by Polyphen2 to be damaging. |
Ghani et al., 2016 |
W78Ter |
NHD : Pathogenic | Substitution | Substitution | Missense | Coding | Exon 2 | Brain atrophy has been reported. |
Predicted to result in truncated protein lacking transmembrane and cytoplasmic domains. |
Paloneva et al., 2002 |
D86V |
FTD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown; MRI of a patient carrying both the Y38C and D86V variants, showed cortical atrophy, thinning of the corpus callosum, periventricular white-matter abnormalities,ventricular enlargement and probable globus pallidus calcification. |
Decreased cell-surface expression and defective N-linked glycosylation. |
Guerreiro et al., 2013 |
D87N |
AD : Possible Risk Modifier | Substitution | Substitution | Missense | Coding | Exon 2 | Typical AD pathology in single described case (Braak Stage 6). |
Decreased binding to lipoproteins in cell-free assay, but increased ligand-stimulated activation in reporter cell line. |
Guerreiro et al., 2013 |
G90Vfs |
NHD : Pathogenic | Deletion | Deletion | Frame Shift | Coding | Exon 2 | Unknown; MRI showed leukoencephalopathy and cerebral atrophy. |
Unknown. |
Klünemann et al., 2005 |
T96K |
FTD : Possible Risk Modifier | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown; carriers of the T96K/W191X/L211P variants have lower levels of sTREM2 in CSF, compared with noncarriers. |
Increased binding to cell-derived ligands and increased activation by phospholipids seen in reporter cell line. |
Thelen et al., 2014 |
R98W |
AD : Unclear Pathogenicity, FTD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown. |
Predicted to be probably damaging by PolyPhen2. |
Guerreiro et al., 2013 |
A105Rfs |
NHD : Pathogenic | Substitution | Substitution | Frame Shift | Coding | Exon 2 | Unknown; imaging showed cerebral atrophy, leukoencephalopathy, thinning of the corpus callosum, basal ganglia calcification. |
Unknown. |
Klünemann et al., 2005 |
A105T |
FTD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown. |
Predicted to be neutral by SIFT and by the PolyPhen 2 HumVar algorithm, but to be possibly damaging by PolyPhen2 HumDiv. |
Thelen et al., 2014 |
A105V |
AD : Benign | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown. |
Unknown. |
Sims et al., 2017; Jin et al., 2015 |
S116C |
AD : Unclear Pathogenicity, FTD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown. |
Cell-surface expression similar to that of wild-type TREM2 heterologously expressed in HEK293 cells. |
Borroni et al., 2014 |
V126G |
NHD : Pathogenic | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown; MRI showed leukoencephalopathy with sparing of arcuate fibers, cerebral atrophy, and thinning of the corpus callosum. |
Poor cell-surface expression and defective for N-linked glycosylation in the Golgi. |
Klünemann et al., 2005 |
A130S |
AD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown. |
Normal protein maturation when heterologously expressed in HEK293 cells. |
Sirkis et al., 2016 |
A130V |
AD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 2 | Unknown. |
Predicted by SIFT to be damaging. |
Jiao et al., 2014 |
c.391+1G>A |
FTD : Pathogenic | Substitution | Splicing Alteration | | Non-Coding | Intron 2 | Magnetic resonance imaging revealed cortical atrophy, ventricular enlargement, pronounced thinning of the corpus callosum, and diffuse white-matter hyperintensites. Calcification of the globus pallidus was observed by computed tomography. |
In heterologous expression systems, this variant was found to cause abnormal splicing (i.e., retention of intron 2). Although TREM2 protein levels were not assayed in these in vitro studies, the lack of soluble TREM2 in the proband’s CSF suggests abnormal protein expression or processing. |
Li et al., 2019 |
c.392-352T>C (rs7748513) |
AD : Possible Risk Modifier | Substitution | Substitution | | Non-Coding | Intron 2 | Unknown. |
Unknown. |
Reitz et al., 2013 |
D131D |
AD : Benign | Substitution | Substitution | Silent | Coding | Exon 3 | Not applicable. |
Unknown. |
Sims et al., 2017 |
L133L |
AD : Unclear Pathogenicity, FTD : Unclear Pathogenicity | Substitution | Substitution | Silent | Coding | Exon 3 | Unknown. |
Unknown. |
Cuyvers et al., 2014 |
D134G |
NHD : Pathogenic, FTD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 3 | Brain atrophy. |
Unknown. |
Paloneva et al., 2002 |
R136W |
AD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 3 | Unknown. |
Normal protein maturation, decreased total and cell-surface expression in HEK 293 cells; when stimulated by phospholipids, reporter cells expressing the R136W variant responded similarly to cells expressing wild-type TREM2. |
Jin et al., 2014 |
R136Q |
AD : Benign, FTD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 3 | Unknown. |
Normal protein maturation, slightly reduced cell-surface expression in HEK293 cells. |
Sims et al., 2017 |
G145W |
AD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 3 | Unknown, but MRI of proband showed diffuse cortical atrophy. |
Leads to a change in protein conformation (shortening of the intrinsically disordered region between the immunoglobulin-like and transmembrane domains), and reduces cellular response to activation of the TREM2/DAP12 signaling complex. |
Karsak et al., 2020 |
E151K |
AD : Benign | Substitution | Substitution | Missense | Coding | Exon 3 | Unknown. |
Normal protein maturation but reduction in overall expression in HEK 293 cells; when stimulated by phospholipids, reporter cells expressing the E151K variant responded similarly to cells expressing wild-type TREM2. |
Jonsson et al., 2013; Sims et al., 2017 |
H157Y |
AD : Possible Risk Modifier | Substitution | Substitution | Missense | Coding | Exon 3 | Unknown. |
Increases shedding of sTREM2. Reduces activation in response to phospholipid ligands and decreases phagocytosis. |
Jiang et al., 2016; Jiang et al., 2016; Sims et al., 2017 |
c.482+1G>A |
FTD : Pathogenic | Substitution | Splicing Alteration | | Non-Coding | Intron 3 | Unknown; MRI showed periventricular white-matter hyperintensities, enlargement of the lateral ventricles, and thinning of the corpus callosum. |
Unknown. |
Chee et al., 2017 |
c.482+2T>C |
NHD : Pathogenic, FTD : Unclear Pathogenicity | Substitution | Splicing Alteration | Deletion | Non-Coding | Intron 3 | Unknown; imaging showed brain atrophy, basal ganglia calcification, and hypoperfusion in the frontotemporal cortex of NHD patient. |
Exon 3 skipping, with deletion of exons 2 and/or 4, and the presence of premature or original stop codons; two truncated TREM2 protein products detected, which are likely to be nonfunctional. |
Paloneva et al., 2002; Numasawa et al., 2011 |
S162R |
AD : Unclear Pathogenicity, FTD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 4 | Unknown. |
Normal protein maturation in HEK293 cells. |
Cuyvers et al., 2014; Sirkis et al., 2016 |
K186N |
NHD : Pathogenic | Substitution | Substitution | Missense | Coding | Exon 4 | Brain atrophy. |
Predicted to result in defects in signal transduction.
|
Paloneva et al., 2002 |
A192T |
AD : Benign | Substitution | Substitution | Missense | Coding | Exon 4 | Unknown. |
Predicted to be possibly damaging by Polyphen2. |
Sims et al., 2017; Jiang et al., 2016 |
A196T |
AD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 4 | Unknown. |
Unknown. |
Sirkis et al., 2016 |
W198Ter |
FTD : Pathogenic | Substitution | Substitution | Missense | Coding | Exon 4 | Unknown; frontal lobe atrophy seen on MRI. |
Premature truncation. |
Giraldo et al., 2013 |
L211P |
AD : Possible Risk Modifier, FTD : Possible Risk Modifier | Substitution | Substitution | Missense | Coding | Exon 4 | Unknown; lower levels of sTREM2 in CSF of T96K/W191X/L211P carriers. |
Predicted tolerated in silico by SIFT and benign by PolyPhen-2. |
Jin et al., 2015 |
H215Q |
AD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 4 | Unknown. |
Unknown. |
Jin et al., 2014 |
T223I |
AD : Benign, FTD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 4 | Unknown. |
Predicted by Polyphen2 to be benign, by SIFT to be tolerated and by SNPs&Go to be neutral; normal protein maturation in HEK293 cells. |
Sims et al., 2017 |
S183C |
AD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 4 of transcript variant 2 | Unknown. |
Predicted to be tolerated by SIFT but possibly damaging by PolyPhen-2; classified as a polymorphism by Mutation Taster. |
Jiang et al., 2016; Zhang et al., 2020 |
W191Ter |
AD : Unclear Pathogenicity | Substitution | Substitution | Nonsense | Coding | Exon 4 of transcript variant 2 | Unknown. |
Unknown. |
Jin et al., 2015 |
c.*73G>A (rs2234258) |
AD : Unclear Pathogenicity, FTD : Unclear Pathogenicity | Substitution | Substitution | | Non-Coding | Exon 5, 3' UTR | Unknown. |
Unknown. |
Cuyvers et al., 2014 |
W200C |
AD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 4 of transcript variant 2 | Unknown. |
Predicted to be probably damaging by Polyphen2. |
Jiang et al., 2016 |
E202D |
AD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 4 of transcript variant 2 | Unknown. |
Unknown. |
Jin et al., 2014; Jin et al., 2015 |
L205P |
AD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 4 of transcript variant 2 | Unknown. |
Predicted by SIFT to be damaging, but by Polyphen2 to be benign. |
Ghani et al., 2016 |
G219C |
AD : Unclear Pathogenicity | Substitution | Substitution | Missense | Coding | Exon 4 of transcript variant 2 | Unknown. |
Predicted by SIFT to be damaging but by Polyphen2 to be benign. |
Ghani et al., 2016 |